ChemPartner PharmaTech Co Ltd (SHE:300149) — Market Cap & Net Worth
Market Cap & Net Worth: ChemPartner PharmaTech Co Ltd (300149)
ChemPartner PharmaTech Co Ltd (SHE:300149) has a market capitalization of $727.95 Million (CN¥4.97 Billion) as of May 2, 2026. Listed on the SHE stock exchange, this China-based company holds position #10636 globally and #3121 in its home market, demonstrating a -8.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ChemPartner PharmaTech Co Ltd's stock price CN¥9.99 by its total outstanding shares 497963992 (497.96 Million). Analyse cash efficiency ratio of ChemPartner PharmaTech Co Ltd to see how efficiently the company converts income to cash.
ChemPartner PharmaTech Co Ltd Market Cap History: 2015 to 2026
ChemPartner PharmaTech Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.27 Billion to $727.95 Million (-5.97% CAGR).
ChemPartner PharmaTech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ChemPartner PharmaTech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.48x
ChemPartner PharmaTech Co Ltd's market cap is 0.48 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.27 Billion | $315.81 Million | $59.47 Million | 4.01x | 21.28x |
| 2016 | $1.40 Billion | $258.64 Million | $64.98 Million | 5.40x | 21.49x |
| 2017 | $1.11 Billion | $275.35 Million | $57.81 Million | 4.02x | 19.15x |
| 2018 | $1.06 Billion | $996.92 Million | $161.08 Million | 1.06x | 6.56x |
| 2019 | $962.52 Million | $1.33 Billion | $138.92 Million | 0.72x | 6.93x |
| 2020 | $1.07 Billion | $1.48 Billion | $154.55 Million | 0.72x | 6.92x |
| 2021 | $1.01 Billion | $1.69 Billion | -$402.25 Million | 0.60x | N/A |
| 2022 | $758.55 Million | $1.33 Billion | $378.59 Million | 0.57x | 2.00x |
| 2023 | $557.44 Million | $1.14 Billion | -$916.75 Million | 0.49x | N/A |
| 2024 | $467.81 Million | $970.20 Million | -$226.47 Million | 0.48x | N/A |
Competitor Companies of 300149 by Market Capitalization
Companies near ChemPartner PharmaTech Co Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to ChemPartner PharmaTech Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
ChemPartner PharmaTech Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, ChemPartner PharmaTech Co Ltd's market cap moved from $1.27 Billion to $ 727.95 Million, with a yearly change of -5.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥727.95 Million | +4.50% |
| 2025 | CN¥696.62 Million | +48.91% |
| 2024 | CN¥467.81 Million | -16.08% |
| 2023 | CN¥557.44 Million | -26.51% |
| 2022 | CN¥758.55 Million | -24.62% |
| 2021 | CN¥1.01 Billion | -5.88% |
| 2020 | CN¥1.07 Billion | +11.09% |
| 2019 | CN¥962.52 Million | -8.93% |
| 2018 | CN¥1.06 Billion | -4.51% |
| 2017 | CN¥1.11 Billion | -20.73% |
| 2016 | CN¥1.40 Billion | +10.34% |
| 2015 | CN¥1.27 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of ChemPartner PharmaTech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $727.95 Million USD |
| MoneyControl | $727.95 Million USD |
| MarketWatch | $727.95 Million USD |
| marketcap.company | $727.95 Million USD |
| Reuters | $727.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ChemPartner PharmaTech Co Ltd
Chempartner Pharmatech Co., Ltd. engages in the microecological nutrition and healthcare businesses worldwide. The company operates in two segments, Microecological Nutrition and Medical Business; and Pharmaceutical Research and Development Service and Production Outsourcing Business. It offers prebiotic products and the provision of microecological medical services. The company provides comprehe… Read more